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Abstract Data analysis ^ not data production ^ is becoming
the bottleneck in gene expression research. Data integration is
necessary to cope with an ever increasing amount of data, to
cross-validate noisy data sets, and to gain broad interdiscipli-
nary views of large biological data sets. New Internet resources
may help researchers to combine data sets across di¡erent gene
expression platforms. However, noise and disparities in exper-
imental protocols strongly limit data integration. A detailed re-
view of four selected studies reveals how some of these limita-
tions may be circumvented and illustrates what can be achieved
through data integration.
" 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Why integration of expression data?
Functional genomics is a new ¢eld of research emerging
from full genome sequencing and from new technologies
which make it possible to quantify mRNA transcripts on a
genome-wide scale in any cell or tissue type. The major gene
expression platforms, Serial Analysis of Gene Expression
(SAGE) [1] and cDNA microarrays [2], were ¢rst proposed
in 1995, followed by oligonucleotide arrays in 1996 [3]. Since
then, the publication rate in the ¢eld has grown exponentially,
reaching 2000 papers for microarrays alone in 2001 [4]. Ap-
plications encompass drug development [5], yeast biology [6],
vaccine design [7], cancer research [8], etc. ^ they are too
numerous to be listed here.
Because they are readily available in electronic format, se-
quence data and expression data open the door to data and
knowledge integration on a scale unprecedented in the history
of biology. Molecular biology would bene¢t if expression data
produced by di¡erent groups on di¡erent systems could be
compared. For example, in cancer research the integration
of high-throughput expression data sets presents an exciting
opportunity to transcend the frontiers in terms of cancer types
that have traditionally fragmented the ¢eld. What is common
between cancers? Do metastatic cells arise from the same pro-
cesses ^ and thus share potential drug targets ^ in di¡erent
tumors? Is it possible to classify cancers on the basis of their
expression pro¢le? Such questions are coming within reach.
High-throughput gene expression data sets are subject to
noise and error [9,10]. This is compounded by the statistical
di⁄culties raised by massive multiple hypothesis testing when
identifying di¡erentially expressed genes [10]. Thus, indepen-
dent validation of di¡erential expression is required before
drawing conclusions from microarray or SAGE experiments.
Polymerase chain reaction (PCR)-based protocols or North-
ern blots used for this purpose measure expression on a per-
gene basis. Only a dozen among hundreds of putatively di¡er-
entially expressed genes are validated in a typical study. The
inherent power of high-throughput technology is not matched
by high-throughput validation [11,12]. Comparing data sets
produced by di¡erent groups on di¡erent platforms could in-
crease con¢dence in expression results for many more genes
than is tractable with classical validation [11,12].
Although validation of expression results could be im-
proved, a dozen genes of potential interest are identi¢ed and
con¢rmed in a typical microarray study. Hundreds of such
studies are published every year. This is much more informa-
tion than the research community can possibly follow up with
detailed experimental studies. Furthermore, it is doubtful
whether investigators producing data on a high-throughput
scale squeeze all of the information buried in it [13]. This is
information overload [14] : data analysis, not data generation,
is becoming the main bottleneck. Re-use and integration
could help researchers to form the comprehensive views of
existing data needed to better prioritize experimental e¡orts.
This minireview addresses integration of expression data
from a practical perspective. The major resources available
to match the probes of heterogeneous platforms are presented.
Next, we review what is known about results reproducibility,
hence comparability, within and across platforms. Finally, we
analyze the design of four particularly successful studies, and
derive strategies to overcome noise and platform heterogene-
ity issues that may prevent the integration of expression data.
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2. Data, standards, and tools
Large public gene expression databases are already, or will
soon be, operational (Table 1), and many groups publish ex-
pression data on their web sites. Hundreds of data sets are
readily available. Cell and journals of the Nature publishing
group require authors to make their expression data publicly
available, more journals are considering a similar move as
databases become more user-friendly [15].
The substantial ^ and fast growing ^ number of publicly
available data sets is of limited value, however, as long as a
number of compatibility issues are not resolved. Investigators
use di¡erent platforms, di¡erent sample preparation proto-
cols, di¡erent data formats, and di¡erent data normalization
algorithms, making it di⁄cult to compare data sets. Data
format standardization is being addressed at an international
level by the Microarray Gene Expression Data Society [16].
The Minimum Information About a Microarray Experiment
(MIAME) guidelines aim at unambiguously interpreting mi-
croarray data and at subsequently allowing independent ver-
i¢cation [17]. MIAME compliance is mandatory for publica-
tion of microarray data in Cell, The Lancet, Nature journals
and Science. The Microarray Gene Expression Mark-up Lan-
guage (MAGE-ML) provides the formal infrastructure to ex-
change and store MIAME-compliant data [16]. Major gene
expression public databases are using MAGE-ML, or will use
it in the near future (A. Brazma, ArrayExpress, personal com-
munication).
Data storage and exchange are the ¢rst steps toward data
integration. The data sets to be pooled use di¡erent probe
sequences and formats: nonamer tags for SAGE, spotted
cDNA sequences or oligonucleotides for microarrays. In ad-
dition, mutants or orthologs of the same genes may be used in
the data sets to be integrated. Thus, a next step is to construct
maps between disparate sets of probes in order to compare
data sets. Several resources useful to this end are available
over the Internet (Table 1). RESOURCERER [18] provides
maps between the probe sets of various commercial and non-
commercial platforms which encompass human, mouse and
rat. SOURCE [19] and EnsMart automate the construction
of association tables between various database identi¢cation
numbers and sequence annotations. For example, the user
may submit a list of GenBank IDs to EnsMart and request
the corresponding A¡ymetrix0 probe IDs, LocusLink IDs,
UniGene IDs, Gene Ontology information, etc. UniGene
[20] is a grouping of GenBank mRNA entries by sequence
similarity. A set of similar sequences is called a cluster.
Maps may be constructed by associating probes that belong
to the same UniGene cluster, i.e. with same UniGene ID.
LocusLink [21] provides locus-to-sequence and to-UniGene
associations useful for cross-species mapping. Once the probes
of the data sets under investigation have been related to one
another, one can proceed to further comparison.
3. How comparable are expression data sets?
Constructing probe libraries, printing arrays, collecting
samples and hybridizing them require many steps. A range
of technical options (reviewed in [22]) which may impact the
¢nal result are available at each of these steps, and each one
of them may incur noise [23]. The complexity of the protocols
together with the measurement errors may undermine cross-
platform integration. If microarrays and SAGE measure any-
thing objective, however, one may expect that results obtained
for mRNA samples collected under one particular biological
condition and assessed with one platform carry over to other
platforms for biologically comparable samples. To what ex-
tent is this veri¢ed?
High reproducibility of measurements within a given plat-
form has been reported for cDNA microarrays [24,25],
A¡ymetrix0 oligonucleotide microarrays [23,26], and SAGE
[27,28]. None of these studies compared samples and hybrid-
ization procedures from di¡erent laboratories. To the best of
our knowledge, how the reported reproducibility carries over
to experiments performed in di¡erent laboratories has not
been systematically investigated. In the case of microarrays,
comparison between arrays of the same type cannot detect
sequence errors. Up to 30% of the spotted probes did not
match the expected gene sequence on arrays from one vendor
[29]. This shortcoming highlights the relevance of cross-plat-
form validation. High-throughput experiments lead to useful
¢ngerprinting of tissues. In this case the comprehensiveness of
the probe set and the exact identity of the represented genes
are less crucial. This is not the case, however, if detailed bio-
logical insights are to be obtained.
Surprisingly, little information is available regarding agree-
ment between platforms. A Spearman correlation of 0.8 was
found between the 200 most di¡erentially expressed tran-
scripts in an A¡ymetrix0 microarray analysis and the corre-
sponding transcripts in a SAGE library [30]. In another study,
SAGE tags present at a frequency of 6 in 76 000 or more were
also detected in more than 80% of 43 A¡ymetrix0 microar-
rays [31]. Taken together, these results suggest a good agree-
ment between these two platforms at medium to high expres-
sion levels.
Yuen et al. [32] compared A¡ymetrix0 and cDNA micro-
arrays by focusing on 47 genes which were also tested with
quantitative real-time PCR. Both platforms detected 16 out of
17 up- or down-regulated genes, and no non-regulated genes
were detected as regulated. Both platforms underestimated
fold change, although cDNA arrays did so in a predictable
and correctable way. By contrast, Kuo et al. [33] found a poor
correlation between A¡ymetrix0 and cDNA microarray data.
They used the raw, non-normalized, data generated by spot
quanti¢cation softwares. Better correlation might have been
found with appropriate normalizations. Unlike Yuen et al.
[32], the data sets they compared originated from two unre-
lated laboratories.
The dual-channel cDNA technology [2] measures simulta-
neously hybridization of spotted probes with the target
mRNA preparation and with a reference mRNA preparation.
Many options are available to prepare reference mRNA. For
example, in a tumor vs. normal tissue set-up, some groups
compare expression in tumor with expression in normal tis-
sues from the same individual, others use pooled normal tis-
sues from several individuals, still others favor tightly cali-
brated custom-made mRNA preparations, depending on the
questions asked. This diversity of protocols is an hindrance
when comparing data sets.
Overall, the limited number of formal cross-platform com-
parison studies suggests that data may be comparable at me-
dium and high expression levels. In addition, reference dispar-
ities will limit comparison in the case of cDNA arrays. We
suggest that any intergroup collaboration should begin with
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method standardization and cross-validation of results ob-
tained on the same cellular material.
4. Four case studies
Although quantitative information is lacking about the de-
gree of correlation between platforms, several groups have
been successful at integrating expression data sets.
Rhodes et al. [12] pooled four published and publicly avail-
able prostate cancer data sets generated by independent labo-
ratories using A¡ymetrix0 or dual-channel cDNA microar-
rays. The null hypothesis that di¡erentially expressed genes
di¡er among studies was tested for each combination of
two, three, and four data sets. For each combination of
data sets a gene-speci¢c false discovery rate, i.e. an estimate
of the probability of ¢nding di¡erential expression of that
gene by chance, was computed for all genes present in all
data sets in the combination. As expected, combination with
more data sets led in general to increased con¢dence in di¡er-
ential expression estimates. About 90 genes were found di¡er-
entially expressed with a false discovery rate under 0.05. Val-
idating 90 genes with classical PCR-based protocols would be
costly and cumbersome. The approach of Rhodes et al. [12]
re-uses public data and is automated.
Ramaswamy et al. [34] searched predictors of metastasis in
primary tumors by analyzing ¢ve published microarray data
sets generated by independent laboratories on several
A¡ymetrix0 platforms, and the Rosetta0 inkjet platform.
They compared the expression pro¢les of 12 metastatic ad-
enocarcinomas of diverse tissue origin with the pro¢les of 64
primary tumors. One hundred and twenty-eight genes distin-
guished metastatic from primary tumors. Remarkably, some
primary tumors showed a expression pro¢le characteristic of
metastatic tumors, leading the investigators to the hypothesis
that early signs of metastasis could be present in some pri-
mary tumors. To test this hypothesis, they took another data
set from 62 stage I and II primary lung tumors and applied
hierarchical clustering in the space of the 128 metastasis-spe-
ci¢c genes, i.e. all other genes were ignored. Two main clusters
highly correlated with the original primary vs. metastatic tu-
mor distinction were found. Patients whose primary tumor
bore the metastasis signature had a signi¢cantly shorter sur-
vival time. Further re¢nement of the model reduced the 128
gene signature to 17 genes. This simpli¢ed signature could
reproduce the lung tumor data set results on other data
sets: 21 prostate cancer samples, 78 small stage I breast car-
cinomas, and 60 medulloblastomas. Interestingly, the signa-
ture did not correlate with survival in 58 di¡use large B cell
lymphoma samples, in line with the view that hematopoietic
tumor cells use speci¢c navigation mechanisms. The metasta-
sis-speci¢c signature was found from mRNA samples ex-
tracted from many cells ^ a result also supported by an earlier
breast cancer study [35]. This ¢nding challenges the widely
held view that metastasis arises from rare cells with metastatic
potential, and supports the view that many cells in primary
tumors have this potential [36]. It is further shown that the
signature applies to many types of cancers.
Expression data may also be integrated with other types of
high-throughput data. Thousands of protein^protein interac-
tions (PPI) have been detected in yeast with two-hybrid assays
[37,38] and mass spectroscopy [39,40]. Little is known about
the artifacts of these methods. Remarking that proteins can
interact in a cell only if they are co-expressed, Kemmeren et
al. [11] integrated these data with several published yeast gene
expression data sets in order to increase con¢dence in PPI
data. They ¢rst selected one two-hybrid data set and a set
of expression pro¢les from one study and used them as a
test bed to develop a method to correlate PPI and co-expres-
sion. Next, they applied this method to all the PPI data and
326 expression pro¢les compiled from ¢ve unrelated studies
addressing diverse issues such as cell cycle, response to un-
folded proteins, or response to pheromone treatment. A few
hundred PPIs in the two-hybrid and mass spectroscopy data
sets had been previously established through independent in-
vestigations. Depending on the data set and the selected con-
¢dence threshold, 54^71% of these PPI exhibited co-expres-
sion. This brings credence to the approach. Since protein
expression can be controlled at the post-transcriptional level,
a complete concordance is not expected. Out of 5342 two-
hybrid-derived PPIs, 973 were also co-expressed, and may
be considered functional with increased con¢dence. One of
the protein partners had a functional annotation while the
other did not in 328 of these 973 PPIs. Kemmeren et al.
propose transferring the functional annotation of the known
protein to the other, hypothesizing that two interacting pro-
teins are most likely involved in the same biological process.
To test this idea they deleted the gene encoding the non-an-
notated protein partner of an annotated protein for ¢ve PPIs.
Table 1
Selected web sites
Major databases for high-throughput gene expression
ArrayExpress (European Bioinformatics Institute) http://www.ebi.ac.uk/arrayexpress
Cancer Genome Anatomy Project (National Cancer Institute) http://www.cgap.nci.nih.gov
Children National Medical Center Microarray Center http://www.microarray.cnmcresearch.org/pgadatatable.asp
Gene Expression Omnibus (National Center for Biotechnology Information) http://www.ncbi.nih.gov/geo
Stanford Microarray Database http://www.genome-www5.stanford.edu/MicroArray/SMD
Data standardization
Microarray Gene Expression Data Society http://www.mged.org
Major tools to match (and annotate) probes
EnsMart (EMBL and Wellcome Trust Sanger Center) http://www.ensembl.org/EnsMart
LocusLink (NCBI) http://www.ncbi.nlm.nih.gov/LocusLink
RESOURCERER (The Institute for Genomic Research) http://www.pga.tigr.org/tigr-scripts/magic/r1.pl
SOURCE (Stanford University) http://www.source.stanford.edu/cgi-bin/sourceSearch
UniGene (NCBI) http://www.ncbi.nih.gov/UniGene
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In all cases the deletion resulted in the same phenotype as
observed following deletion of the annotated partner, suggest-
ing that annotation can be transferred.
Integration of gene expression data sets and genome maps
has established the view that expressed genes are not ran-
domly distributed along chromosomes, they form clusters
[41^44]. In the arguably most quantitative study on this sub-
ject so far, Spellman and Rubin [44] compiled expression data
from 88 unrelated experimental conditions in Drosophila as-
sessed on 267 A¡ymetrix0 microarrays from six independent
laboratories, and mapped them to the Drosophila chromo-
some maps. They calculated the pair-wise correlation of ex-
pression of adjacent genes across the 88 conditions. These
correlations were then averaged over windows sliding along
the chromosome. Windows of di¡erent sizes were tested in
order to measure the length of stretches of co-expressed genes.
About 200 clusters of 10^30 co-regulated genes, representing
20% of all genes, span the Drosophila genome. Spellman and
Rubin repeated their analysis on a data set from which ho-
mologous genes located in a same neighborhood in chromo-
some maps were removed. The number of clusters dropped to
176. Thus, recent gene duplication and function similarity
between the resulting homologs is not a general explanation
for the observed 200 clusters. Next, they mapped each gene to
its Gene Ontology (GO) functional categories. The Gene On-
tology [45] is a human-curated structured vocabulary which
describes gene products in terms of chemical and biological
functions, and of cellular location. Genes within a given clus-
ter were not biased toward a same set of functional GO cat-
egories, suggesting that they are not functionally related. Cal-
culation of correlations between cluster location and map of
Drosophila polytene chromosomes failed to identify a relation
with band morphology in polytene chromosomes. Taken to-
gether, these results led Spellman and Rubin to the provoca-
tive conclusion that clusters occur because transcription is
sloppy: a by-product of the unfolding of the chromatin struc-
ture around a gene being expressed is the expression of its
neighbors. This e¡ect may contribute to illegitimate transcrip-
tion. From the point of view of data integration, expression
data were mapped on genome maps, the resulting cluster
structure was then correlated with sequence data, GO catego-
ries, and chromosome band morphology. All these calcula-
tions were performed on a genome-wide scale.
5. Strategies to cope with noisy and heterogeneous data sets
The noise inherent in high-throughput methods and the
heterogeneity of experimental protocols may obscure biolog-
ically relevant relations between data sets and preclude data
integration. The studies reviewed above cope with these issues.
In the following, we extract the general strategies that were
used for doing so.
Rhodes et al. [12] focused on genes di¡erentially expressed
in several data sets. These data sets represent the same bio-
logical condition, prostate cancer, but rely on di¡erent plat-
forms. Di¡erential expression was assessed independently for
each gene in each data set. The calculation grouping results
from the various data sets operated on a statistical con¢dence
measure, p-value, not on expression level. This strategy avoids
direct comparisons of data sets and related cross-platform
normalization issues.
As mentioned earlier, Ramaswamy et al. [34] identi¢ed
from one data set a small set of genes distinguishing primary
tumors with metastatic potential from primary tumors with-
out such potential. They then used it to cluster data sets in
order to assess its validity and generality across many types of
cancers. Focusing on a small number of genes dramatically
reduced the search space when performing clustering, making
it more likely to ¢nd relevant cluster structures. In addition,
data sets were not pooled together. Ramaswamy et al. [34]
compared qualitatively the conceptual end-results of indepen-
dent analysis of each data set, namely the applicability of the
signature to the data. Reducing data, i.e. lowering resolution,
is likely to have an averaging e¡ect making integration less
sensitive to noise.
The studies of Kemmeren et al. [11] and Spellman and
Rubin [44] relied on co-expression of genes over a compen-
dium [46], i.e. a collection of expression pro¢les measured
under diverse and unrelated biological conditions. Whether
expression is in£uenced by the details of cell culture protocols
or by interesting biological features is irrelevant as long as it
re£ects cell function. Although correlation calculations may
still be obscured by di¡erences in mRNA preparation and/
or hybridization between data sets, it is resistant to di¡erences
in downstream procedures on living material.
Most importantly, the speci¢cs of various platforms and
laboratory procedures are much more likely to introduce dif-
ferences between data sets than to introduce similarities. Thus,
the cross-platform, cross-study, approach is conservative
when it comes to discovering properties shared by data sets.
All four studies presented above focus on shared properties:
expression patterns shared by genes [11,44], genes di¡eren-
tially expressed common to data sets [12], and the universality
of a signature of metastasis among cancers [34]. Because data
integration is about elaborating synthetic views, it naturally
brings focus on similarity between data sets. The resulting
knowledge is more reliable because shared features are more
likely to be robust with respect to noise and to the speci¢cs of
experimental procedures.
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